General information about U.S. regulatory definitions, not legal, medical, or manufacturing advice.

"Custom peptide manufacturing" spans very different legal regimes depending on the peptide's length, its intended use, and who is making it. The single most consequential fact is a number: 40 amino acids is the line U.S. regulations draw between a drug and a biologic. Below is a primary-sourced map of how peptides are classified and what manufacturing rules attach to each classification.

Is a custom peptide regulated as a drug or a biologic?

It depends on length: a peptide of 40 or fewer amino acids is regulated as a drug, while a longer amino-acid polymer is a biologic. FDA defines a "protein" as "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size" under 21 CFR § 600.3(h)(6). Because the statutory definition of "biological product" lists "protein" among its enumerated categories in 42 U.S.C. § 262(i), a peptide that is 40 amino acids or shorter falls below the protein prong and is therefore not a biological product — it is regulated as a drug.

One nuance matters for multi-chain molecules: when a protein's amino-acid chains associate naturally, size is measured by the total number of amino acids across all chains, not the length of any single chain, per 21 CFR § 600.3(h)(6). A short synthetic peptide that assembles into a larger natural complex can therefore cross the 40-residue threshold.

What manufacturing standards govern peptide drug products?

Finished peptide drug products must be made under current Good Manufacturing Practice (cGMP), and a new peptide drug cannot be sold across state lines without an approved application. The cGMP rules for finished pharmaceuticals live in 21 CFR Part 211, which is organized into 11 subparts (A–K) covering organization and personnel, buildings and facilities, equipment, control of components, production and process controls, packaging and labeling, holding and distribution, laboratory controls, records and reports, and returned or salvaged products.

On top of manufacturing quality, market entry is gated. Under 21 U.S.C. § 355(a), no person may introduce or deliver a new drug into interstate commerce unless an approval of an application — an NDA under subsection (b) or an ANDA under subsection (j) — is effective for that drug. For a novel peptide drug, cGMP compliance and an approved application are separate, cumulative requirements.

Can a compounding pharmacy make a custom peptide?

Yes, but only under narrow conditions defined by FD&C Act § 503A. A compounded drug is exempt from cGMP, new-drug-approval, and certain labeling requirements only if it is compounded by a licensed pharmacist (in a state-licensed pharmacy or federal facility) or a licensed physician for an identified individual patient pursuant to a valid prescription, per 21 U.S.C. § 353a(a).

The starting material is constrained too. Under 21 U.S.C. § 353a(b)(1)(A), bulk drug substances must comply with an applicable USP or National Formulary monograph if one exists; if no monograph exists, the substance must be a component of an FDA-approved drug or appear on an FDA-developed list — and in every case it must come from a registered manufacturer and arrive with a valid certificate of analysis. There is also a distribution ceiling: a § 503A compounder may not ship compounded drugs out of state in quantities exceeding 5% of the pharmacy's total prescription orders unless its state has a memorandum of understanding with FDA, under 21 U.S.C. § 353a(b)(3)(B).

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

The core difference is scale and cGMP: a 503A pharmacy compounds patient-specific prescriptions and is exempt from cGMP, while a 503B outsourcing facility can compound without patient-specific prescriptions but must follow cGMP. An outsourcing facility is defined in 21 U.S.C. § 353b(d)(4) as a facility at one geographic location engaged in compounding sterile drugs that has elected to register with FDA — it need not be a licensed pharmacy and need not obtain patient-specific prescriptions.

That flexibility comes with obligations. Under 21 U.S.C. § 353b, a 503B facility must register with FDA annually (October–December), report its compounded drugs twice yearly (June and December) with active ingredients, product forms, and quantities, pay establishment fees, and label products "This is a compounded drug." Critically, and unlike § 503A compounding, a 503B facility's drugs are not exempt from cGMP — the statute conditions the § 503B exemptions on cGMP compliance.

Are research-use peptides regulated the same way?

No — research-use peptides are a distinct category from the approved-drug, compounded-drug, and biologic pathways described above, and none of the § 505, § 503A, or § 503B provisions convert a research chemical into a therapeutic product. If you evaluate a supplier, apply the same documentation logic the statutes themselves demand of compounders — a valid certificate of analysis from an identified source, as required for compounding bulk substances under 21 U.S.C. § 353a(b)(1)(A).

Browse the Cornerstone Peptide catalog, where every item is listed with its identity and analytical documentation so you can verify what you're evaluating against that standard.

Frequently asked questions

Is a peptide a drug or a biologic? It depends on length. A protein — a biologic — is defined as an amino-acid polymer greater than 40 amino acids under 21 CFR § 600.3(h)(6), so a peptide of 40 or fewer amino acids is regulated as a drug.

What standard governs peptide drug manufacturing? Finished peptide drug products must be made under cGMP in 21 CFR Part 211, and a new peptide drug needs an effective approved application before interstate sale under 21 U.S.C. § 355.

Can a compounding pharmacy make custom peptides? Only under § 503A: a licensed pharmacist or physician, an individual-patient prescription, permitted bulk substances, and a valid certificate of analysis, per 21 U.S.C. § 353a.

How is a 503B facility different? A 503B outsourcing facility registers with FDA, may compound sterile drugs without patient-specific prescriptions, and must follow cGMP, per 21 U.S.C. § 353b.